Latest Healthcare News

Clever Culture Systems has sold its APAS Independence instrument to Novo Nordisk for a comprehensive evaluation across the pharmaceutical giant’s manufacturing network, marking a key step in its global sales strategy.

Compumedics Limited has reported record sales orders and a return to profitability in FY25, setting the stage for robust growth in FY26 driven by US market traction and SaaS expansion.

Alterity Therapeutics has responded to an ASX inquiry about its recent share price and volume spike, confirming no undisclosed information but highlighting imminent clinical data releases and investor roadshows as possible drivers.

Imugene Limited reports promising Phase 1b trial results for azer-cel, an off-the-shelf CAR T therapy, showing a 75% overall response rate in relapsed diffuse large B-cell lymphoma patients. The company plans to engage the FDA later this year to discuss pivotal trial design.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

Proteomics International’s subsidiary OxiDx has unveiled a pioneering test that detects muscle damage in thoroughbred racehorses, promising to transform recovery management in the racing industry. The test’s commercial launch is slated for the second half of 2025.

Pacific Edge reports steady demand for its Cxbladder cancer diagnostic tests despite losing Medicare coverage and transitioning US customers to a new test. The company is advancing clinical evidence and a $21 million capital raise to support growth and regain coverage.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

InteliCare has launched a three-month trial of its AI-powered platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy with a leading aged care provider.

TALi Digital has completed a modest capital raise through a 1-for-6 entitlement offer, coinciding with its strategic acquisition of You Can Do It! Education, signaling a push into social-emotional learning.

Invion Limited’s IVXO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing and investor confidence.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.